1f
12
9
1a
8
20
8
49
16
8
19
1
49
2
8
1b
1d
18
79
35
1d
2 29
1d
25
35
Clyde E. Markowitz, M.D.
77Associate Professor of Neurology at the Hospital of the University of Pennsylvania
7
60
Department: Neurology
4
1
b
1d
46
Contact information
59
4
3
3
3
2
4
b
1f
59
Hospital of the University of Pennsylvania
1d 3 West Gates Building
35 3400 Spruce Street
Philadelphia, PA 19104
26
1d 3 West Gates Building
35 3400 Spruce Street
Philadelphia, PA 19104
2e
Office: 215-662-4521
32 Fax: 215-349-5579
24
97
32 Fax: 215-349-5579
24
Email:
cmarkowi@mail.med.upenn.edu
12
cmarkowi@mail.med.upenn.edu
13
Education:
21 9 B.S. 24 (Business Administration) c
40 State University of New York at Buffalo, 1982.
21 5 2f (Post-baccalaureate pre-med program) c
2c Columbia University, 1986.
21 9 M.D. 15 (Medicine) c
48 Columbia Univ. College of Physicians & Surgeons, 1990.
c
3
3
21
21 9 B.S. 24 (Business Administration) c
40 State University of New York at Buffalo, 1982.
21 5 2f (Post-baccalaureate pre-med program) c
2c Columbia University, 1986.
21 9 M.D. 15 (Medicine) c
48 Columbia Univ. College of Physicians & Surgeons, 1990.
c
1f
Post-Graduate Training
24 3c Internal Medicine, Columbia-Presbyterian Medical Center 29 New York, N.Y., 1990-1991.
24 57 Resident in Neurology, Neurological Institute-Columbia-Presbyterian Medical Center 10 New York, N.Y. 1b , 1991-1994.
24 7b Neuroimmunology/MS-Research/Clinical Postdoc. Fellowship, Neurological Institute- Columbia-Presbyterian Medical Center 29 New York, N.Y., 1994-1998.
c
3
25
24 3c Internal Medicine, Columbia-Presbyterian Medical Center 29 New York, N.Y., 1990-1991.
24 57 Resident in Neurology, Neurological Institute-Columbia-Presbyterian Medical Center 10 New York, N.Y. 1b , 1991-1994.
24 7b Neuroimmunology/MS-Research/Clinical Postdoc. Fellowship, Neurological Institute- Columbia-Presbyterian Medical Center 29 New York, N.Y., 1994-1998.
c
17
Certifications
28 3c National Board of Medical Examiners, 1991.
28 43 American Board of Psychiatry and Neurology, 1995.
28 54 American Board of Psychiatry and Neurology- Recertification, 2005.
c
3
8b
Permanent link28 3c National Board of Medical Examiners, 1991.
28 43 American Board of Psychiatry and Neurology, 1995.
28 54 American Board of Psychiatry and Neurology- Recertification, 2005.
c
2 29
21
1e
1d
24
2b
29
27
23
150 Cehelyk EK, Harvey DY, Grubb ML, Jalel R, El-Sibai MS, Markowitz CE, Berger JR, Hamilton RH, Chahin S: Uncovering the association between fatigue and fatigability in multiple sclerosis using cognitive control. Mult Scler Relat Disord. 27: 269-275, October 2018.
129 Fox E, Markowitz C, Applebee A, et al : Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the oratorio study (ENCORE). J Neurol Neurosurg Psychiatry 89(A14), 2018.
e3 Sahin N, Selouan R, Markowitz CE, Melhem ER, Bilello M: Limbic pathway lesions in patients with multiple sclerosis. Acta Radiol. 57(3): 341-7, March 2016.
1a6 Salim Chahin, MD; Deborah Miller, PhD; Reiko Sakai; James Wilson; Clyde Markowitz, MD; Dina Jacobs, MD; Ari Green, MD; Peter A. Calabresi, MD; Elliot M. Frohman, MD; Steven Galetta, MD; Laura Balcer, MD, MSCE: Fatigue in Multiple Sclerosis: Relation to Quantitative Neurologic and Visual Outcomes. Multiple Sclerosis and related disorders May 2015.
be Jose Torres, Amy Pruitt, Laura Balcer, Steven Galetta, Clyde Markowitz, Nabila Dahodwala: Analysis of the treatment of neuromyelitis optica 2 2 50 Journal of the Neurological Sciences 351(1), Feb 2015.
19a Salim Chahin, Deborah Miller, Reiko E. Sakai, James A. Wilson, Teresa Frohman, Clyde Markowitz, Dina Jacobs, Ari Green, Peter A. Calabresi, Elliot M. Frohman, Steven L. Galetta, Laura J. Balcer: Relation of quantitative Visual and neurologic outcomes to fatigue in multiple sclerosis. Multiple Sclerosis and Related Disorders 4(4), 2015.
a8 Edward Fox, Barbara Green, Clyde Markowitz, Ronald Murray, Andrew D Goodman, Stephen J Glenski, Pippa Loupe, Jo Nita Cogburn 2 80 : The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis 3a BMC Neurology 14(1), april 2014.
af Patricia K Coyle, Bruce A Cohen, Thomas Leist, Clyde Markowitz, Merrikay Oleen-Burkey, Marc Schwartz, Mark J Tullman, Howard Zwibel 2 7b : Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes 3a BMC Neurology 14(1), March 2014.
18e Miller Aaron E, Cohen Bruce A, Krieger Stephen C, Markowitz Clyde E, Mattson David H, Tselentis Helen N: Constructing an adaptive care model for the management of disease-related symptoms throughout the course of multiple sclerosis--performance improvement CME. Multiple sclerosis (Houndmills, Basingstoke, England) Aug 2013.
2c
7
1d
1f
Selected Publications
180 Fox EJ, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, Fiore D, Pei J, Musch B, Giovannoni G: Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Mult Scler. November 2018.150 Cehelyk EK, Harvey DY, Grubb ML, Jalel R, El-Sibai MS, Markowitz CE, Berger JR, Hamilton RH, Chahin S: Uncovering the association between fatigue and fatigability in multiple sclerosis using cognitive control. Mult Scler Relat Disord. 27: 269-275, October 2018.
129 Fox E, Markowitz C, Applebee A, et al : Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the oratorio study (ENCORE). J Neurol Neurosurg Psychiatry 89(A14), 2018.
e3 Sahin N, Selouan R, Markowitz CE, Melhem ER, Bilello M: Limbic pathway lesions in patients with multiple sclerosis. Acta Radiol. 57(3): 341-7, March 2016.
1a6 Salim Chahin, MD; Deborah Miller, PhD; Reiko Sakai; James Wilson; Clyde Markowitz, MD; Dina Jacobs, MD; Ari Green, MD; Peter A. Calabresi, MD; Elliot M. Frohman, MD; Steven Galetta, MD; Laura Balcer, MD, MSCE: Fatigue in Multiple Sclerosis: Relation to Quantitative Neurologic and Visual Outcomes. Multiple Sclerosis and related disorders May 2015.
be Jose Torres, Amy Pruitt, Laura Balcer, Steven Galetta, Clyde Markowitz, Nabila Dahodwala: Analysis of the treatment of neuromyelitis optica 2 2 50 Journal of the Neurological Sciences 351(1), Feb 2015.
19a Salim Chahin, Deborah Miller, Reiko E. Sakai, James A. Wilson, Teresa Frohman, Clyde Markowitz, Dina Jacobs, Ari Green, Peter A. Calabresi, Elliot M. Frohman, Steven L. Galetta, Laura J. Balcer: Relation of quantitative Visual and neurologic outcomes to fatigue in multiple sclerosis. Multiple Sclerosis and Related Disorders 4(4), 2015.
a8 Edward Fox, Barbara Green, Clyde Markowitz, Ronald Murray, Andrew D Goodman, Stephen J Glenski, Pippa Loupe, Jo Nita Cogburn 2 80 : The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis 3a BMC Neurology 14(1), april 2014.
af Patricia K Coyle, Bruce A Cohen, Thomas Leist, Clyde Markowitz, Merrikay Oleen-Burkey, Marc Schwartz, Mark J Tullman, Howard Zwibel 2 7b : Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes 3a BMC Neurology 14(1), March 2014.
18e Miller Aaron E, Cohen Bruce A, Krieger Stephen C, Markowitz Clyde E, Mattson David H, Tselentis Helen N: Constructing an adaptive care model for the management of disease-related symptoms throughout the course of multiple sclerosis--performance improvement CME. Multiple sclerosis (Houndmills, Basingstoke, England) Aug 2013.
2c